Coordinator for multiple gene sequencing on cancer tissue (FoundationOne, Cambridge, MA02141, USA), September 2017-Present

Size: px
Start display at page:

Download "Coordinator for multiple gene sequencing on cancer tissue (FoundationOne, Cambridge, MA02141, USA), September 2017-Present"

Transcription

1 CURRICULUM VITAE ET STUDIORUM NAME Veronica Varchetta DOB: 23/07/1987 POB: Rome Italy PRESENT TITLE AND AFFILIATION Oncology Assistant and Coordinator, Specific Research Area: Translational and Clinical Oncology Clinical Project Manager, Specific Research Area: Translational and Clinical Coordinator for Liquid Biopsy (SCED Solid Cancer Early Detection) in collaboration with University Tor Vergata, Rome and Bioscience Institute, San Marino Republic, January 2017-Present Coordinator for Liquid Biopsy (Free and CTC DNA sequencing molecular characterization for diagnosis and treatment) in collaboration with Genoma Group, Roma, April 2017-Present Coordinator for multiple gene sequencing on cancer tissue (FoundationOne, Cambridge, MA02141, USA), September 2017-Present CITIZENSHIP Italian LANGUAGE SPOKEN English C1+ HOME ADDRESS Via Londra 4, Ciampino, Roma, Italy Telephone: ; mobile: !1

2 OFFICE ADDRESS CaTheDra Medical Oncology Dept Villa Margherita, Rome, Italy , Viale di Villa Massimo, 48, Roma Telephone: Fax: EDUCATION Degree-Granting Education Degree in Political Science, University Niccolò Cusano, Rome, Italy (3 years Degree: 97/110), March 2013 Degree in Political Science, University Niccolò Cusano, Rome, Italy (Master Degree 100/110), July 2015 Master of Healthcare Management cum laude, University Niccolò Cusano, Rome, Italy, January 2018 Postgraduate Training in Medical Science Certification in Clinical Oncology Multidisciplinary Organization, April 2015, University Health Board, GIG CYMRU NHS WALES GCP Training Certificate, 2015 GCP Training Certificate, 2016 GCP Training Certificate, 2017 Training Specific Courses 2 Oncoworkshop in Nanotechnologies and Innovations: New landscapes in treatment of cancer disease, Bari, March 27-28, 2015 New supportive therapies in Oncology, Bologna, May 11-12, 2015 Methods and Strategies in Clinical Colorectal Cancer, Florence, May 14, 2015!2

3 The Biological Bases of new Target therapies in Lung Cancer. Lung Unit, Sharing the Experience, Rome, May 21, 2015 PRACTICE Meeting on Colorectal Cancer, Rome July 8, 2015 SABC Standing Advisory Board on Colorectal Cancer, Milan Jule 13, 2015 Grande Lung Slam meeting, Roma October, 2015 AIOM National Meeting, October, Convegno/Workshop NICSO, Milano, December, 2015 ASCO University Course, 2016 Gastrointestinal Cancer Symposium MOC Review, Total AMA PRA Category Credit Awarded: 2.00, San Francisco, Jan 2016 Consensus Conference sulla Global Care del Paziente con Tumore Testa/Collo Ricorrente Metastatico, Milan, 5/05/2016 Choosing Wisely nel trattamento del carcinoma colorettale, Rome May 15, 2016 Updates on Oncological Abdominal Surgery, Rome May 12-13, 2016 ASCO 2016 Annual Meeting, ASCO University Course, 2016 Annual Meeting Chicago June 2016 ASCO 2017 Annual Meeting, ASCO University Course, 2017 Annual Meeting Chicago June 2017 ASCO University Course, 2018 Gastrointestinal Cancer Symposium MOC Review, Total AMA PRA Category Credit Awarded: 2.00, San Francisco, Jan 2018 EXPERIENCE/SERVICE Oncology Assistant and Coordinator, Specific Research Area: Translational and Clinical!3

4 Oncology Clinical Project Manager, Specific Research Area: Translational and Clinical MERIT AWARDS Grant to take part to International PrIME Expert Practice in Pancreatic Cancer Meeting, Budapest, Sept 2017 Grant for Clinical Project Manager in Immunoncology at Sukumvit Hospital, Bangkok (NCI, Thailand) Center of Excellence for Cancer Treatment and Immunotherapy Research (CECTIR) SCIENTIFIC COORDINATION AT NATIONAL OR INTERNATIONAL CONFERENCES Change from laboratory to clinic trial: Ca.The.Dra. Meeting, Rome, June 26-27, 2015 Consensus Conference Regionale sulla Global Care del paziente con Tumore Polmonare: Chirurgia, Clinica e Biologia Molecolare, Le Evidenze Internazionali nelle Linee Guida e Percorsi Terapeutici in Regione Lazio, Regione Lazio, November, 2016 National Conference on Lung and Colorectal Cancer, San Camillo/Forlanini Hospitals, Rome, April 2018 PUBLICATIONS ORIGINAL ARTICLES 1) Mancuso A, Varchetta V, Montagnese F, Sibio S, Sica G, Muscaritoli M, Giordano G, Brandi R, Leone A., On Behalf CaTheDra Multidisciplinary Cancer Group, A pilot study of Abraxane (Nab Paclitaxel) as second or third-line therapy for metastatic K-Ras mutated pancreatic cancer patients, 2 Oncoworkshop in Nanotechnologies and Innovations: New landscapes in treatment of cancer disease, Bari, March 27-28, ) Mancuso A, Varchetta V, Montagnese F, Sibio S, Sica G, Muscaritoli M, Soda G, Brandi R, On Behalf CaTheDra Multidisciplinary Cancer Group, PD-1 Expression and Regorafenib Clinical Efficacy on Refractory Pancreatic Cancer Patient, Chicago, May 2016, Abstr. E15684!4

5 3) Varchetta V, Campanella C, Caggiati A, Granati L and Mancuso A, Recurrence of venous thromboembolism among non small cell lung cancer patients treated with EGFR inhibitor, ICTHIC, Abstr ) Mancuso A, Varchetta V, Montagnese F, Campanella C, Brandi R, Vitale M, Soda G, Plasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc), Gastrointestinal Cancer Symposium, Abstr 702 5) Mancuso A, Varchetta, Campanella C, Montagnese F, et al., Circulating tumor cells (CTC) genotyping in lung cancer diagnosis and decision making, accepted for poster presentation at Biotechnology Meeting Dubai, July 2018 WEB OR MAGAZINE EDUCATIONAL ACTIVITY 1) (Faculty Organization) 2) 3) WEBSITE Villa Margherita Oncology Platform EXTRA MEDICAL EMPLOYMENTS Board Member of CaTheDra Oncological Department, March, 2015-present RESEARCH Founded Protocols Sub-Investigator and Datamanager of the Study Smartfish SF-C002, 2016 Sub-Investigator and Datamanager of the Study Array: A Multicenter, Randomized, Open Label Phase III Study of Encorafenib + Cetuximab +/- Binimetinib vs Irinotecan + Cetuximab with a safety Lead-in of Encorafenib + Binimetinib + Cetuximab in patients with BRAF V600E-mutant Metastatic Colorectal Cancer!5

6 PROFESSIONAL MEMBERSHIPS National and International Member of Italian Association of Medical Oncology, 2015-present Member of Oncological Network, Supportive care NICSO, 2015-present Member of ESMO, 2016-present Member of ASCO, 2016-present Roma 26/01/2018!6

Plasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc)

Plasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc) Plasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc) Authors: Andrea Petricca Mancuso, Veronica Varchetta, Fabrizio

More information

Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer

Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,

More information

AIOM GIOVANI Perugia, Luglio 2017

AIOM GIOVANI Perugia, Luglio 2017 AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica

More information

ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria

ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,

More information

Y L L NOTHING BUT THIS. NOTHING IS SIMPLE IN ONCOLOGY.

Y L L NOTHING BUT THIS. NOTHING IS SIMPLE IN ONCOLOGY. ID Y L L NOTHING BUT THIS. A NOTHING IS SIMPLE IN ONCOLOGY. WHAT DOES IDYLLA TM M E AN FOR CANCER PATIENTS? High Precision Diagnostics for Personalized Medicine RAPID TREATMENT INITIATION 1 Test results

More information

Europass Curriculum Vitae

Europass Curriculum Vitae Europass Curriculum Vitae Personal information First name(s) / Surname(s) Address Via Gattamelata 64 35128 Padova Telephone(s) +39 049.8215953/5910 E-mail(s) vittorina.zagonel@iov.veneto.it Nationality

More information

Franchi Massimo Piergiuseppe. Policlinico Universitario G Rossi, Azienda Ospedaliera Universitaria Integrata di Verona Verona 2012

Franchi Massimo Piergiuseppe. Policlinico Universitario G Rossi, Azienda Ospedaliera Universitaria Integrata di Verona Verona 2012 Curriculum Vitae Personal information First name(s) / Surname(s) Franchi Massimo Piergiuseppe Telephone(s) 0039 045 8122720 Fax(es) 0039 045 8123394 E-mail(s) Nationality massimo.franchi@univr.it Italian

More information

Objectives. Briefly summarize the current state of colorectal cancer

Objectives. Briefly summarize the current state of colorectal cancer Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard

More information

LIQUID BIOPSY: TRACKING CANCER

LIQUID BIOPSY: TRACKING CANCER A.R.Ger.On ONLUS SYMPOSIUM LIQUID BIOPSY: TRACKING CANCER 29-30 April 2016 prog ram Pierre-Auguste Renoir Chemin montant dans les hautes herbes SYMPOSIUM LIQUID BIOPSY: TRACKING CANCER President Paola

More information

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann

Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell

More information

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014

More information

Description of Procedure or Service. Policy. Benefits Application

Description of Procedure or Service. Policy. Benefits Application Corporate Medical Policy KRAS, NRAS, BRAF Mutation Analysis and Related File Name: Origination: Last CAP Review: Next CAP Review: Last Review: kras_nras_braf_mutation_analysis_and_related_treatment_in_metastatic_colorectal_cancer

More information

Liquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director

Liquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director Liquid Biopsy Jesus Garcia-Foncillas MD PhD Director Main issues about liquid biopsies New paradigm: Precision Medicine Heterogeneity & Dynamics Surrogate mirror for the tumor CTCs in colon cancer ctdna:

More information

VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH

VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY 8-9 April 2011 Viareggio, Italy Chair: M. Aapro, CH Dear Colleagues, The European School of Oncology is

More information

Colorectal Cancer in the Coming Years: What Can We Expect?

Colorectal Cancer in the Coming Years: What Can We Expect? Colorectal Cancer in the Coming Years: What Can We Expect? Clara Montagut, MD, PhD Hospital Universitari del Mar, Barcelona, Spain Memorial Sloan Kettering Cancer Center, New York, United States What Are

More information

Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015

Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015 Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring Mark G. Erlander, Ph.D., CSO CHI Next Generation Summit August 19,2015 Circulating Tumor DNA (ctdna) Tumor cells Main Advantages of

More information

Current Position. Research activities - Publications. Athanasios Kotsakis

Current Position. Research activities - Publications. Athanasios Kotsakis Athanasios Kotsakis Athanasios Kotsakis was born in Athens in 1968 and is married with 3 children. He studied Medicine at the University of Athens and continued his training in Internal Medicine at the

More information

Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux

Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux 2 ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working groups E Van Cutsem A Sobrero

More information

Colorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital

Colorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?

More information

October 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference

October 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference The premier conference for annual updates in lung cancer 23rd Annual Conference October 12 13, 2018 New York Marriott Marquis New York, New York Reserve your place today: thoraciccancermeeting.com Perspectives

More information

CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES

CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli

More information

CURRICULUM VITAE PERSONAL DETAILS: RAHAL, MOHAMED

CURRICULUM VITAE PERSONAL DETAILS: RAHAL, MOHAMED PERSONAL DETAILS: CURRICULUM VITAE NAME: RAHAL, MOHAMED MARITAL STATUS: ADDRESS: Married, 3 children King Fahad Specialist Hospital Oncology Department PO BOX 14563 DAMMAM 31434 Kingdom of Saudi Arabia

More information

Basket Trials: Features, Examples, and Challenges

Basket Trials: Features, Examples, and Challenges : Features, s, and Challenges Lindsay A. Renfro, Ph.D. Associate Professor of Research Division of Biostatistics University of Southern California ASA Biopharm / Regulatory / Industry Statistics Workshop

More information

OHTAC Recommendation. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer

OHTAC Recommendation. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer OHTAC Recommendation KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer Presented to the Ontario Health Technology Advisory Committee in August, 2010 December 2010 Issue Background In February

More information

ESMO ACROSS ONCOLOGY. WORLDWIDE. Josep Tabernero. ESMO President. ESMO SUMMIT MIDDLE EAST Friday, 6 th April 2018

ESMO ACROSS ONCOLOGY. WORLDWIDE. Josep Tabernero. ESMO President. ESMO SUMMIT MIDDLE EAST Friday, 6 th April 2018 ESMO ACROSS ONCOLOGY. WORLDWIDE Josep Tabernero ESMO President ESMO SUMMIT MIDDLE EAST Friday, 6 th April 2018 ESMO IN A NUTSHELL Europe s leading Medical Oncology Society ESMO is the leading European

More information

Infographic (right): ESMO 2014 record breaking Congress

Infographic (right): ESMO 2014 record breaking Congress ESMO 2014 Congress Scientific Meeting Report Precision Medicine in Cancer Care 26-30 September 2014 Madrid, Spain Summary The European Society for Medical Oncology (ESMO) Congress, held September 26 to

More information

CURRICULUM VITAE. Date of birth July 30th, 1960 PERSONAL INFORMATIONS. Curriculum vitae of Alberto Matteelli pag. 1/6

CURRICULUM VITAE. Date of birth July 30th, 1960 PERSONAL INFORMATIONS. Curriculum vitae of Alberto Matteelli pag. 1/6 E U R O PA S S CURRICULUM VITAE PERSONAL INFORMATIONS Surname/First name Alberto Matteelli Address Passirano (Brescia) Piazza Europa 24, ZIP 25050 Telephone (s) +39.030.3995802 (office) Mobile: +30.339.3344033

More information

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine

Molecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical

More information

Prof. Pietro Ruggieri CURRICULUM VITAE. Full Professor and Chairman of the Department of Orthopedics and Orthopedic Oncology at University of Padova

Prof. Pietro Ruggieri CURRICULUM VITAE. Full Professor and Chairman of the Department of Orthopedics and Orthopedic Oncology at University of Padova Prof. Pietro Ruggieri CURRICULUM VITAE Date of birth 04/26/1958 Title Full Professor and Chairman of the Department of Orthopedics and Orthopedic Oncology at University of Padova Current Assignment Professor

More information

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress

First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase

More information

Colorectal Cancer: Critical review

Colorectal Cancer: Critical review AIOM POST-ASCO 2018 Updates and Review from Chicago Milano, June 15-16, 2018 Colorectal Cancer: Critical review Alfredo Falcone, MD Department of Oncology and Translational Medicine University of Pisa

More information

Pancreatic Cancer: Medical Therapeutic Approaches

Pancreatic Cancer: Medical Therapeutic Approaches Pancreatic Cancer: Medical Therapeutic Approaches Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat Pancreatic cancer: Why so difficult

More information

How is Merck supporting innovation in oncology?

How is Merck supporting innovation in oncology? How is Merck supporting innovation in oncology? We sponsor research and advanced medical education globally, reflecting our commitment to science, education and patient care We support the development

More information

ESMO Clinical Practice Guidelines. ECCO GUIDELINES FORUM Brussels, November 27

ESMO Clinical Practice Guidelines. ECCO GUIDELINES FORUM Brussels, November 27 ESMO Clinical Practice Guidelines ECCO GUIDELINES FORUM Brussels, November 27 ESMO Clinical Practice Guidelines ESMO Consensus Conferences ESMO Pocket & Mobile Guidelines ESMO Guides for Patients History

More information

Bristol-Myers Squibb Independent Medical Education

Bristol-Myers Squibb Independent Medical Education Bristol-Myers Squibb Independent Medical Education Request for Educational Support (RFE) Date August 10, 2017 RFE Requestor Information RFE Code Name: Maria Deutsch, MS, PharmD, RPh Title: IME Specialist,

More information

Evolution of the individualized treatment landscape for advanced NSCLC

Evolution of the individualized treatment landscape for advanced NSCLC IASLC Asia Pacific Lung Cancer Conference (APLCC 2016) 13-15 May 2016, Chiang Mai, Thailand Evolution of the individualized treatment landscape for advanced NSCLC Chaired by Tony Mok Empress Grand Hall,

More information

6-8 July Naples, Italy

6-8 July Naples, Italy PRACTICE TEACHING COURSE SCIENTIFIC PROGRAMME Metastatic colorectal cancer: from disease biology to clinical management 6-8 July 2016 - Naples, Italy Metastatic colorectal cancer: from disease biology

More information

CURRICULUM VITAE MAIN POST DEGREE EDUCATION AND CREDIT 1/3

CURRICULUM VITAE MAIN POST DEGREE EDUCATION AND CREDIT 1/3 CURRICULUM VITAE Name: Bruno Family Name : Violante Date of birth: March 27 th, 1961 Education : 1987 Naples University Degree in Medicine and Surgery 1992 Firenze University Degree in Orthopaedic Cum

More information

Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017

Announce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017 AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy 11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor

More information

CURRICULUM VITAE. Chiyoko Kobayashi Frank, Ph.D. Adjunct Faculty, School of Psychology, Fielding Graduate University

CURRICULUM VITAE. Chiyoko Kobayashi Frank, Ph.D. Adjunct Faculty, School of Psychology, Fielding Graduate University CURRICULUM VITAE Chiyoko Kobayashi Frank, Ph.D Adjunct Faculty, School of Psychology, Fielding Graduate University New York Board Certified Psychologist Email: ckobayashi@email.fielding.edu Professional

More information

CURRICULUM VITAE. Associate Clinical Professor of Medicine, UCSF Medical Director, Acute Care for Elders Unit, San Francisco General Hospital

CURRICULUM VITAE. Associate Clinical Professor of Medicine, UCSF Medical Director, Acute Care for Elders Unit, San Francisco General Hospital CURRICULUM VITAE Name: Position: Address: Edgar Pierluissi Associate Clinical Professor of Medicine, UCSF Medical Director, Acute Care for Elders Unit, San Francisco General Hospital 1001 Potrero Avenue

More information

DALLA CAPECITABINA AL TAS 102

DALLA CAPECITABINA AL TAS 102 DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu

More information

CLAUDIA RODELLA CURRICULUM VITAE

CLAUDIA RODELLA CURRICULUM VITAE CLAUDIA RODELLA CURRICULUM VITAE PERSONAL INFORMATION: Date of birth: 16 th May 1988 Place of birth: Brescia (BS) - Italy Nationality: Italian Phone: +39 0303501594 E-mail: claudia.rodella@gmail.com claudia.rodella@cognitiveneuroscience.it

More information

Examples of Selection Criteria for the EAMA

Examples of Selection Criteria for the EAMA Examples of Selection Criteria for the EAMA Category 1 Category 2 Category 3 MD members of the staff with a PhD degree and experience in clinical work, research and education of students of departments

More information

Vectibix. Vectibix (panitumumab) Description

Vectibix. Vectibix (panitumumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix

More information

ESMO Translational Research Fellowship (November 2015 November 2017) Lisa Derosa FINAL REPORT

ESMO Translational Research Fellowship (November 2015 November 2017) Lisa Derosa FINAL REPORT ESMO Translational Research Fellowship (November 2015 November 2017) Lisa Derosa FINAL REPORT Host Institute: Institute Gustave Roussy, Villejuif, France Mentor: Dr. Bernard Escudier Project title: The

More information

Easy Breathing. An asthma management program for Pediatricians, Primary Care Practitioners, and Family Practitioners.

Easy Breathing. An asthma management program for Pediatricians, Primary Care Practitioners, and Family Practitioners. Easy Breathing An asthma management program for Pediatricians, Primary Care Practitioners, and Family Practitioners. The Asthma Center The Asthma Center at Connecticut Children s Medical Center was established

More information

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro

La biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity

More information

UNIVERSITY OF GENOVA CURRICULUM VITAE

UNIVERSITY OF GENOVA CURRICULUM VITAE UNIVERSITY OF GENOVA CURRICULUM VITAE Genova, 07.06.2013 NAME: MOHAMAD MAGHNIE CURRENT TITLE & DEPARTMENT: Associate Professor of Pediatrics Department of Pediatrics, School of Medicine Director, Pediatric

More information

E U R O P E A N PERSONAL INFORMATION. Name Address Telephone Fax MATTEO RAVAIOLI. Date of birth WORK EXPERIENCE

E U R O P E A N PERSONAL INFORMATION. Name Address Telephone Fax  MATTEO RAVAIOLI. Date of birth WORK EXPERIENCE E U R O P E A N C U R R I C U L U M V I T A E F O R M A T PERSONAL INFORMATION Name Address Telephone Fax E-mail MATTEO RAVAIOLI Nationality Italian Date of birth WORK EXPERIENCE 200-2009: surgeon staff

More information

Circulating Tumor DNA in GIST and its Implications on Treatment

Circulating Tumor DNA in GIST and its Implications on Treatment Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna

More information

Ahu Gökçe, Ph.D. Department of Psychology Kadir Has University

Ahu Gökçe, Ph.D. Department of Psychology Kadir Has University 1 CURRICULUM VITAE Ahu Gökçe, Ph.D. Department of Psychology Kadir Has University ahu.gokce@khas.edu.tr EDUCATION 2010 2013: Doctor of Philosophy Department of General and Experimental Psychology, & Munich

More information

Resident Senior, Dept. of Neurosurgery Notre-Dame Hospital University of Montreal, Canada, under the guidance of prof. Jules Hardy.

Resident Senior, Dept. of Neurosurgery Notre-Dame Hospital University of Montreal, Canada, under the guidance of prof. Jules Hardy. Prof. Giulio Maira ACADEMY DEGREES 1968 October 1972 Degree in Medicine and Surgery, Catholic University School of Medicine Rome, Italy (magna cum laude) Specialist in Neurosurgery, University of Genoa,

More information

Curriculum Vitae Europass

Curriculum Vitae Europass Curriculum Vitae Europass PERSONAL INFORMATION Name Work Address Scorsetti Marta SCRMRT67A57G558T Radiotherapy and Radiosugery Department, Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano (MI),

More information

Immunotherapy in Colorectal cancer

Immunotherapy in Colorectal cancer Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute

More information

La biopsia liquida dei tumori: il viaggio. Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome

La biopsia liquida dei tumori: il viaggio. Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome La biopsia liquida dei tumori: il viaggio Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome Must Know Necessary Travel Tips There is lack of drugs to treat all the

More information

INDICATION: COMPENDIA TRANSPARENCY TRACKING FORM

INDICATION: COMPENDIA TRANSPARENCY TRACKING FORM COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Panitumumab INDICATION: Metastatic colorectal cancer, wild-type KRAS mutation, first-line therapy, in combination with infusional fluorouracil, leucovorin, and

More information

OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors

OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University

More information

ASCO Quality Oncology Practice Initiative (QOPI): Implications For A Rapid Learning System For Cancer

ASCO Quality Oncology Practice Initiative (QOPI): Implications For A Rapid Learning System For Cancer ASCO Quality Oncology Practice Initiative (QOPI): Implications For A Rapid Learning System For Cancer Joseph Jacobson, MD Chair, QOPI Steering Committee Salem MA October 6, 2009 American Society of Clinical

More information

Colon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano

Colon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line

More information

Name of Policy: Panitumumab, Vectibix

Name of Policy: Panitumumab, Vectibix Name of Policy: Panitumumab, Vectibix Policy #: 369 Latest Review Date: June 2014 Category: Pharmacology Policy Grade: B Background/Definitions: As a general rule, benefits are payable under Blue Cross

More information

JY Douillard MD, PhD Professor of Medical Oncology

JY Douillard MD, PhD Professor of Medical Oncology Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard

More information

AACE History. ! Founded in 1991 to serve as the active voice for clinical endocrinologists

AACE History. ! Founded in 1991 to serve as the active voice for clinical endocrinologists AACE History! Founded in 1991 to serve as the active voice for clinical endocrinologists! Providing practicing clinical endocrinologists an avenue for the study of the scientific, social, political, and

More information

Roche Investor Relations ASCO Planner 2017

Roche Investor Relations ASCO Planner 2017 Roche Investor Relations ASCO Planner 2017 Saturday, June 3 Session Title: Lung Cancer Non-Small Cell Metastatic Date: Sat, June 3 Time: 8:00 AM 11:30 AM Speaker Name: Ibiayi Dagogo-Jack, MD; Yuichi Takiguchi,

More information

Daniele Santini University Campus Bio-Medico Rome, Italy

Daniele Santini University Campus Bio-Medico Rome, Italy Daniele Santini University Campus Bio-Medico Rome, Italy Anti EGFR therapy and colorectal cancer Cetuximab or Panitumumab Adapted from Ciardiello F. and Tortora G. NEJM 2008;358:1160-74 Who will benefit

More information

CURRICULUM VITAE. Brynie Slome Collins, M.D. Department of Gastroenterology and Nutrition 4650 Sunset Blvd MS 78 Los Angeles, Ca 90027

CURRICULUM VITAE. Brynie Slome Collins, M.D. Department of Gastroenterology and Nutrition 4650 Sunset Blvd MS 78 Los Angeles, Ca 90027 A. PERSONAL INFORMATION CURRICULUM VITAE Name in Full Business Address Brynie Slome Collins, M.D. Department of Gastroenterology and Nutrition 4650 Sunset Blvd MS 78 Los Angeles, Ca 90027 Business Phone

More information

Sergio Bracarda MD, Head, Department of Oncology Azienda USL Toscana Sud-Est Istituto Toscano Tumori (ITT) Ospedale San Donato Arezzo, Italy

Sergio Bracarda MD, Head, Department of Oncology Azienda USL Toscana Sud-Est Istituto Toscano Tumori (ITT) Ospedale San Donato Arezzo, Italy Sergio Bracarda MD, Head, Department of Oncology Azienda USL Toscana Sud-Est Istituto Toscano Tumori (ITT) Ospedale San Donato Arezzo, Italy Milano, 3 marzo 2017 Prostata: Castration resistant HIGHLIGHTS

More information

Immunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC

Immunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG

More information

Qué hemos aprendido hasta hoy? What have we learned so far?

Qué hemos aprendido hasta hoy? What have we learned so far? Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;

More information

Curriculum Vitae Europass

Curriculum Vitae Europass Curriculum Vitae Europass Personal information Name and surname Nicoletta Zerman Address Piazzale Ludovico Scuro 10 VERONA Telephone numbers +39 045 8027437 mobile 335 1804333 Fax 045 8027437 E-mail Nicoletta.zerman@univr.it

More information

La strategia terapeutica per il trattamento del carcinoma del colon-retto metastatico

La strategia terapeutica per il trattamento del carcinoma del colon-retto metastatico VI Corso Nazionale Eventi Formativi AIOM-SIAPEC Roma,15 Giugno 2016 La strategia terapeutica per il trattamento del carcinoma del colon-retto metastatico Francesco Di Costanzo Direttore SC Oncologia Medica

More information

Fellow in Nephrology at University of California, San Francisco 7/1/1982-6/30/1984

Fellow in Nephrology at University of California, San Francisco 7/1/1982-6/30/1984 Curriculum Vitae Haseeb I. Al-Mufti, MD 13939 E 14 th St, Suite 170 San Leandro, CA 94578-2613 660 4 th St, # 349 San Francisco, CA 94107-1618 Office (510) 483-2480 Fax (510) 483-4286 Email: halmufti@renalassociates.org

More information

HeavilyTreated mcrc..whats next?

HeavilyTreated mcrc..whats next? ESMO Preceptorship Programme Gastrointestinal Cancer 20-22 October 2016,Singapore Dr Surendra Pal Chaudhary Dept of Medical Oncology Dr BR Ambedkar Instituite Rotary Cancer Hospital All India Institute

More information

Oncotype DX DX : Colon Cancer Assay: Scientific Publications and Presentations.

Oncotype DX DX : Colon Cancer Assay: Scientific Publications and Presentations. Oncotype DX DX : Colon Cancer Assay: Scientific Publications Scientific and Presentations Publications and Presentations www.oncotypedx.com Oncotype DX : Scientific Publications and Presentations A Tool

More information

Curriculum Vitae Gianluigi Zanusso, M.D., Ph.D.

Curriculum Vitae Gianluigi Zanusso, M.D., Ph.D. Curriculum Vitae Gianluigi Zanusso, M.D., Ph.D. Place and date of birth: Desenzano del Garda, September 21, 1963 Citizenship: Italian Affiliation: Department of Neurosciences, Biomedicine and Movement

More information

CURRICULUM VITAE. Chiyoko Kobayashi Frank, Ph.D. Adjunct Faculty, School of Psychology, Fielding Graduate University

CURRICULUM VITAE. Chiyoko Kobayashi Frank, Ph.D. Adjunct Faculty, School of Psychology, Fielding Graduate University CURRICULUM VITAE Chiyoko Kobayashi Frank, Ph.D Adjunct Faculty, School of Psychology, Fielding Graduate University Psychologist, Center for Cognition and Communication Email: ckobayashi@fielding.edu Professional

More information

Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD

Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives

More information

Sofia Aroca, Paris France

Sofia Aroca, Paris France Sofia Aroca, Paris France University Qualifications 1985 Doctor in dental surgical medicine 1991 Post-graduate of dental biomaterials. University Paris VII, France 1992 Certificate of Periodontology. University

More information

CARCINOMA DEL COLON-RETTO: COSA DICONO LE LINEE GUIDA. Dr.ssa Foltran Luisa Oncologia medica Pordenone

CARCINOMA DEL COLON-RETTO: COSA DICONO LE LINEE GUIDA. Dr.ssa Foltran Luisa Oncologia medica Pordenone CARCINOMA DEL COLON-RETTO: COSA DICONO LE LINEE GUIDA Dr.ssa Foltran Luisa Oncologia medica Pordenone Convegno Regionale AIOM FVG, Palmanova, 14 Maggio 2016 COLORECTAL CANCER FOLLOW-UP Objectives Intensive

More information

Colon cancer: ASCO poster review. Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome

Colon cancer: ASCO poster review. Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome Colon cancer: ASCO poster review Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome a.destefano@istitutotumori.na.it 255 poster examined: my selection Clinical Practice Translational &

More information

Newsletter. What s inside: ISSUE 3 SEPTEMBER 2017

Newsletter. What s inside: ISSUE 3 SEPTEMBER 2017 Newsletter ISSUE 3 SEPTEMBER 2017 I PE WELCOME TO THE THIRD NEWSLETTER OF THE RIBURST STUDY (REDUCING THE INTERNATIONAL BURDEN OF STROKE USING MOBILE TECHNOLOGY) Progress of the Study The study is progressing

More information

Third Line and Beyond: Management of Refractory Colorectal Cancer

Third Line and Beyond: Management of Refractory Colorectal Cancer Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting

More information

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER

MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal

More information

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:

Progress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader: SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental

More information

MUTATION TEST CE IVD. ctnras-braf FEATURES

MUTATION TEST CE IVD. ctnras-braf FEATURES ctnras-braf CE IVD TECHNICAL SHEET IDYLLA ctnras-braf MUTATION TEST The Idylla ctnras-braf Mutation Test, performed on the Biocartis Idylla System, is an in vitro diagnostic test for the qualitative detection

More information

Array BioPharma Jefferies 2016 Global Healthcare Conference. June 9, 2016

Array BioPharma Jefferies 2016 Global Healthcare Conference. June 9, 2016 Array BioPharma Jefferies 216 Global Healthcare Conference June 9, 216 Safe Harbor Statement 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,

More information

If multiple KRAS mutation tests have been performed, refer to the most recent test results.

If multiple KRAS mutation tests have been performed, refer to the most recent test results. Measure #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy

More information

OVERVIEW DAGLI STUDI CLINICI CON NAB-PACLITAXEL Studio GAP. Alberto Zaniboni. Oncologia Medica, Fondazione Poliambulanza Brescia

OVERVIEW DAGLI STUDI CLINICI CON NAB-PACLITAXEL Studio GAP. Alberto Zaniboni. Oncologia Medica, Fondazione Poliambulanza Brescia OVERVIEW DAGLI STUDI CLINICI CON NAB-PACLITAXEL Studio GAP Alberto Zaniboni Oncologia Medica, Fondazione Poliambulanza Brescia A Phase II randomized trial comparing a combination of Abraxane and Gemcitabine

More information

Adjuvant/neoadjuvant systemic treatment of colorectal cancer

Adjuvant/neoadjuvant systemic treatment of colorectal cancer 5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico

More information

See how you can guide the path her cancer takes

See how you can guide the path her cancer takes See how you can guide the path her cancer takes 1 Idylla : easy, rapid and accurate molecular medicine for every patient Paola Valente Strategic Marketing Biocartis 6th meeting on external quality assessment

More information

CURRICULUM VITAE. Meagan B. Farmer, MS, CGC, MBA

CURRICULUM VITAE. Meagan B. Farmer, MS, CGC, MBA CURRICULUM VITAE Meagan B. Farmer, MS, CGC, MBA EDUCATION 2015-2017 M.B.A. Concentrations: Healthcare and Information Systems Management 2010-2012 M.S. Genetic Counseling University of North Carolina at

More information

Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC

Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related

More information

BIOGRAPHY (Date of Birth: 12/09/1972).

BIOGRAPHY (Date of Birth: 12/09/1972). Curriculum vitae Prof. Massimo Miglioretti Associate Professor Department of Psychology University of Milan-Bicocca (ITALY) e-mail: massimo.miglioretti@unimib.it BIOGRAPHY (Date of Birth: 12/09/1972).

More information

ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015. ClinicalTrials.gov ID: NCT

ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015. ClinicalTrials.gov ID: NCT ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt Release Date: 09/30/2015 ClinicalTrials.gov ID: NCT01378962 Study Identification Unique Protocol ID: ML25514 Brief Title: A Study

More information

Positions held: Education/Professional Experience: Curriculum vitae

Positions held: Education/Professional Experience: Curriculum vitae Curriculum vitae Alia Mohamed Ali Attia, M.B.B.cH., M.Sc., MD. Associate Professor of Radiation Oncology at South Egypt Cancer Institute, Assiut University, Assiut, Egypt First name: Alia Middlesbrough

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately

More information

Developing effective ctdna testing services for lung cancer. Executive summary

Developing effective ctdna testing services for lung cancer. Executive summary Developing effective ctdna testing services for lung cancer Executive summary September 2017 Authors: Laura Blackburn, Leila Luheshi, Sandi Deans, Mark Kroese, Hilary Burton Acknowledgements: The PHG Foundation

More information